Fact Check: Manufacturers Set High Drug Prices and Prevent Competition - AHIP

Recent media coverage on high drug prices continues to obscure the primary role drug manufacturers play in the high cost of prescription medications.

Here are the facts:

  • In the first two weeks of 2024, drug manufacturers "raised list prices on 775 brand-name drugs … by a median of 4.5 percent," outpacing "the rate of inflation, which ticked up to 3.4 percent in December," according to research from The Wall Street Journal and 46brooklyn Research.
  • Research has found that the median annual price among new drugs approved by the U.S. Food and Drug Administration (FDA) in 2023 reached $300,000, 35% higher than the previous year.
  • Over the 2009–2018 period, the average price of a prescription for a brand-name drug more than doubled in the Medicare Part D program and increased by 50% in Medicaid.
  • More than 22 cents of every dollar spent on health insurance premiums goes to pay for prescription drugs – more than any other individual category.
  • A recent analysis found that "anti-competitive patent abuse tactics used by big pharmaceutical companies cost U.S. consumers an additional $40.7 billion in prescription drug expenses in one year alone."
  • Research found that pharmaceutical companies filed more than 140 patent applications on average per drug.
  • A recent study found the top 10 brand name drugs in terms of "US net sales revenue in 2021" had a total of 1,429 patents or pending patents.
  • Nearly 60% of voters name pharmaceutical companies as most responsible for rising prescription drug prices.
  • The largest drugmakers in the United States spend just 22 cents out of every dollar on research & development, and a study from JAMA Network found "no relationship" between the price brand name drug makers set and the amount those companies invest in R&D.

Pharmaceutical manufacturers control their drug prices, and they alone can lower them for Americans today. Instead, they continue to raise prices year after year—even several times a year—making health care more expensive for everyone.

Health insurance plans remain committed to keeping prescription drugs as affordable as possible by incentivizing the use of lower-cost, clinically equivalent generics and passing the value of negotiated discounts to patients through lower premiums and drug costs, and saving millions of dollars for patients every day.

Adblock test (Why?)

Comments

Popular posts from this blog

“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more

His Apple Watch warned of an irregular heart rate. Turns out he was having a heart attack | Globalnews.ca - Global News Toronto

“Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet” plus 4 more